# Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

> **NCT05194540** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 136 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tralokinumab

## Key facts

- **NCT ID:** NCT05194540
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-13
- **Primary completion:** 2023-06-06
- **Final completion:** 2023-06-21
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05194540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05194540, "Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05194540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*